PMID: 9449143Feb 4, 1998Paper

Long-term drug treatment of obesity in a private practice setting

Obesity Research
R L AtkinsonD L Ritch

Abstract

This study evaluated the long-term efficacy and safety of the combination of phentermine and fenfluramine for the treatment of obesity in a private practice setting. A total of 1388 consecutive, qualified patients presenting to a private general internal medicine practice in Charlotte, NC, were enrolled with eligibility criteria including: age 18 years to 60 years, 20% over "desirable" bodyweight or body mass index > 27, no serious medical or psychiatric disease, and no contraindications to drug therapy. Patients were instructed in diet, exercise, and behavior modification techniques and received phentermine (15 mg/day to 30 mg/day) and fenfluramine (20 mg/day to 60 mg/day) continuously for over 3 years. Average duration of treatment was 15.9 months, and average weight loss at the last visit was 11.6 kg, or 11.7% of initial bodyweight. For patients completing 1 year of drug treatment, mean weight loss was 16.5 kg, or 16% of initial weight. Weight loss persisted for 2 years, but partial regain was seen at 3 years. The dropout rates were 18% at 6 months, 39% at 1 year, 68% at 2 years, and 78% at 3 years. At 1 year, blood pressure of hypertensive patients fell from 151/95 mm Hg to 127/78 mm Hg, and serum cholesterol and triglyceri...Continue Reading

References

Jun 1, 1992·Drugs·T Silverstone
Dec 14, 1991·Lancet·G A RicaurteA L Martello
Jul 15, 1991·Annals of Internal Medicine·G A Bray
Dec 1, 1990·Disease-a-month : DM·S M Grundy, J P Barnett
Nov 11, 1989·Lancet·B Guy-GrandP Turner
Feb 1, 1984·Annals of Internal Medicine·A P Simopoulos, T B Van Itallie
Jan 1, 1981·Metabolism: Clinical and Experimental·A R GlassT M Boehm
Apr 10, 1995·Archives of Internal Medicine·N R CookC H Hennekens
Aug 1, 1994·The American Journal of Clinical Nutrition·R L Atkinson, V S Hubbard
Nov 1, 1994·The American Journal of Clinical Nutrition·D J Goldstein, J H Potvin
Dec 1, 1993·British Heart Journal·F BrenotG Simonneau
Jan 1, 1993·Annual Review of Nutrition·C Bouchard, L Pérusse
Apr 29, 1993·The New England Journal of Medicine·T YoungS Badr
Aug 29, 1996·The New England Journal of Medicine·J E Manson, G A Faich
Nov 1, 1995·Obesity Research·D H RyanG A Bray
May 1, 1996·Obesity Research·G A BrayK Wilson
Jan 1, 1996·Obesity Research·C Bouchard, L Pérusse
Mar 1, 1993·Obesity Research·D J GoldsteinL A Fludzinski

❮ Previous
Next ❯

Citations

Nov 26, 2009·Clinical and Experimental Medicine·Ramazan SariErkan Coban
Apr 29, 2010·Current Diabetes Reports·Frank L Greenway, George A Bray
Feb 22, 2002·The New England Journal of Medicine·Susan Z Yanovski, Jack A Yanovski
Mar 29, 2008·Metabolic Syndrome and Related Disorders·Mary C VernonEric C Westman
Aug 24, 1999·Current Opinion in Nephrology and Hypertension·Z Huang, A Reddy
Dec 19, 2008·American Journal of Therapeutics·Richard B Rothman, Michael H Baumann
Apr 9, 2009·American Journal of Therapeutics·Richard B Rothman
Feb 19, 2011·Journal of Obesity·Mariela Glandt, Itamar Raz
May 1, 2013·Drug Design, Development and Therapy·Gina CosentinoGabriel I Uwaifo
Aug 7, 2010·Pharmacology, Biochemistry, and Behavior·G A Kennett, P G Clifton
Nov 26, 1999·Obesity Research·F L GreenwayS R Smith
Sep 1, 2008·Journal of Diabetes Science and Technology·David C Klonoff, Frank Greenway
Sep 12, 2018·Annals of Plastic Surgery·Soobin LimFrank H Lau
Jun 24, 2004·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·R SariG Yazicioglu
Dec 6, 2006·International Journal of Obesity : Journal of the International Association for the Study of Obesity·L D WhighamR L Atkinson
Oct 9, 2019·European Journal of Clinical Nutrition·Richard L Atkinson
Oct 12, 2004·Endocrine Research·Ramazan SariUmit Karayalcin
Feb 10, 2021·International Journal of Obesity : Journal of the International Association for the Study of Obesity·N V DhurandharI Macdonald

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.